Market Overview

JMP Securities Speculates How End Of Amgen Collaboration Could Affect BIND Therapeutics


In a report published Thursday, JMP Securities analyst Michael G. King reiterated a Market Outperform rating and $30.00 price target on BIND Therapeutics (NASDAQ: BIND).

In the report, JMP Securities noted, “BIND Therapeutics announces the close of its Accurin nanomedicine collaboration with Amgen (AMGN, NC); reiterate our Market Outperform rating and $30 price target based on our DCF, CAGR, and comparable company valuation methodologies.

"The research collaboration with Amgen, launched in January 2013, was directed at developing an Accurin-based formulation of an undisclosed proprietary small molecule for the treatment of solid tumors, BIND was eligible to receive up to $201MM in potential development and commercial milestones. Excluding these from our model (which was predominantly back-end loaded) bears an incremental negative impact to our valuation by DCF ($29.23 versus $31.74 previously).

"We retain a high level of conviction with BIND-014 and the Accurin development platform, supported by encouraging preliminary objective response data with BIND-014 in KRAS mutant NSCLC, compelling preclinical data from the ongoing collaboration with AstraZeneca (AZN, NC) using an Accurin formulation of barasertib, and the recently announced collaboration with Roche (RHHBY, NC) for non-oncology indications. We view the Roche collaboration as a source of future upside; however, it is difficult to discount at present given a lack of visibility. We remain buyers on any potential weakness resulting from this announcement.”

BIND Therapeutics closed on Wednesday at $12.88.

Latest Ratings for BIND

Apr 2016Cowen & Co.DowngradesOutperformMarket Perform
Apr 2016JMP SecuritiesDowngradesMarket OutperformMarket Perform
Mar 2016JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for BIND
View the Latest Analyst Ratings

Posted-In: JMP Securities Michael G. KingAnalyst Color Reiteration Analyst Ratings


Related Articles (BIND)

View Comments and Join the Discussion!

Latest Ratings

VREXNorthland SecuritiesInitiates Coverage On42.0
EAMorgan StanleyMaintains88.0
ELMorgan StanleyMaintains178.0
SPLKMorgan StanleyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Stocks Hitting 52-Week Highs

UPDATE: Deutsche Bank Downgrades ResMed Following CMS Release